Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up

“…It is well known that patients with long-standing IBD treated with immunomodulatory drugs may be more susceptible to developing lymphoproliferative disease [29][30][31][32] . Even though the use of TNF-α blocking agents has been associated with an increased risk of developing lymphoma [32] , a finding, however, not confirmed by the data of a large USbased CD registry (TREAT) [22] , we did not observe any cases of hematologic malignancy in our study population.…”

Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections

“…2 However, several reports linked infliximab use with the incidence of bacterial and opportunistic infections. [3][4][5][6] More clarity on the potential risk of serious bacterial infections is necessary for a more informed benefit-risk assessment for use of infliximab in patients with inflammatory bowel disease (IBD). Clostridium difficile infections (C. difficile) are of particular concern in light of the impact this particular infection has on patients with IBD, including hospitalization rates and even potentially mortality, although there is currently no evidence of an increased risk for C. difficile infections by infliximab.…”

“…4 The only population-based study addressing this important issue of safety with Infliximab consisted of a cohort of 217 patients with inflammatory bowel disease (IBD) in Stockholm County, Sweden between January 1999 and April 2001. 5 A total of 11 medical centres contributed to the study; these centres were the only ones administering Infliximab during this time period. Forty-one patients (18.9%) experienced a serious event from January 1999 to April 2001.…”

Sepsis, the Liver and the Gut

“…Reactivation or development of tuberculosis has been reported in 24/100,000 patients with rheumatoid arthritis on anti-TNF therapy, compared with 6/100,000 not receiving such treatment. [78,79] Reports of severe sepsis in patients with IBD while taking Azathioprine have also been described. [80,81] Azathioprine and 6-mercaptopurine are used in patients with moderate to severe CD or UC.…”